One New Long COVID Case Every Minute in the United States
- Mar 9
- 10 min read
Updated: Apr 2
A Transparent Reconstruction of Current Incidence Using Public Surveillance Anchors
By Cynthia Adinig
This paper is part of the CYNAERA US-CCUC series
Key Findings and Summary
Long COVID continues to grow in the United States even though routine COVID-19 tracking has declined. Many infections are no longer captured through testing data, which makes it harder to estimate how many people are currently developing Long COVID.
This report estimates current Long COVID incidence using publicly available public health data. The analysis combines CDC hospitalization surveillance with established burden estimates and recent research on Long COVID risk after infection (Centers for Disease Control and Prevention 2026a; Bowe, Xie, and Al-Aly 2022; Bosworth et al. 2023).
Based on these inputs, current SARS-CoV-2 infections in the United States are estimated at roughly 54,000 per day. When current Long COVID risk estimates of 2–6 percent are applied to those infections, and the population already living with Long COVID is accounted for, the result is an estimated 1,000–2,900 new Long COVID cases per day. The central estimate is approximately 1,900 new cases daily.
This means the United States is currently seeing about 1 new Long COVID case every minute.
If transmission levels remain similar to what we see today, the country may continue to experience roughly 300,000–600,000 new Long COVID cases each year. These estimates reflect when illness begins rather than when it is diagnosed. Because many infections are never formally reported, the true burden is likely higher.
The purpose of this analysis is to show clearly how current Long COVID incidence can be estimated using publicly available data. By laying out the assumptions and calculations step by step, the report provides a framework that researchers, policymakers, and public health planners can use to better understand how Long COVID continues to accumulate in the United States.
Why Estimating Long COVID Now Matters
Long COVID, also called post-acute sequelae of SARS-CoV-2 infection, is increasingly recognized as a chronic illness that can affect multiple organ systems after COVID-19 infection. In 2024 the National Academies of Sciences, Engineering, and Medicine defined Long COVID as an infection-associated chronic condition that persists for at least three months and can appear as a continuous, relapsing, or progressive illness affecting one or more organ systems (National Academies of Sciences, Engineering, and Medicine 2024).
Researchers have documented neurological, cardiovascular, metabolic, and immune system effects linked to the condition. While scientific understanding of Long COVID has advanced rapidly, estimating how many new cases are occurring today remains challenging. Earlier in the pandemic, daily case counts provided a clear signal of infection trends. Today, routine case reporting has declined substantially, and many infections are not captured through testing data. Because of this change, public health agencies increasingly rely on statistical models that use hospitalizations and other indicators to estimate the total number of infections occurring in the population (Centers for Disease Control and Prevention 2026a; Centers for Disease Control and Prevention 2026b).
Most Long COVID research has focused on how many people have developed the condition since the pandemic began. Fewer analyses estimate how many people are entering the disease state now, during the reinfection era. This report focuses on that question. Using publicly available surveillance data and conservative assumptions drawn from the research literature, it estimates current Long COVID incidence in the United States.
Definitions
For the purposes of this analysis, Long COVID is defined as persistent or recurring symptoms that continue for at least three months after a SARS-CoV-2 infection and reduce a person’s baseline level of functioning. This definition is consistent with the 2024 report from the National Academies of Sciences, Engineering, and Medicine (National Academies of Sciences, Engineering, and Medicine 2024).
A new case refers to the first time an individual enters the Long COVID disease state. Remission does not remove individuals from lifetime case counts because symptoms may return or fluctuate over time. An infection refers to any SARS-CoV-2 infection, including confirmed, probable, or asymptomatic infections. Because many infections are not captured through testing systems, models must estimate total infections using indirect indicators such as hospitalization surveillance.
Who Is at Risk
The working United States population for 2026 is approximately 335 million people. Corrected prevalence modeling suggests that approximately 48–65 million Americans may have developed Long COVID since the pandemic began. This estimate reflects adjustments for underdiagnosis, surveillance gaps, and structural bias in traditional reporting systems using the CYNAERA US-CCUC prevalence correction framework (Adinig 2026). Long COVID is increasingly recognized as an infection-associated chronic condition that can persist for months or years following SARS-CoV-2 infection (National Academies of Sciences, Engineering, and Medicine 2024). Because individuals already living with Long COVID have entered the disease state, they are removed from the population at risk when estimating new cases. The remaining population represents those still susceptible to developing the condition. This adjustment is expressed as:
S = N − L
where N represents the total population and L represents the number already living with Long COVID. Using the updated prevalence estimate, roughly 81–86 percent of the U.S. population remains susceptible to entering the Long COVID disease state. This correction prevents overestimation by ensuring individuals who already have Long COVID are not counted again as potential new cases.
How Many Are Getting Infected
Direct COVID case reporting has become less reliable as testing has declined. Because of this change, hospitalization data provide a more stable signal for estimating infection levels. The CDC COVID-NET system tracks laboratory-confirmed COVID hospitalizations across a population-based surveillance network and is widely used to estimate national disease burden (Centers for Disease Control and Prevention 2026b). Recent surveillance reports roughly 6,800 COVID hospital admissions per week in the United States.
CDC burden estimation models use hospitalization data as a starting point and apply statistical multipliers to estimate the total number of infections, medical visits, and deaths associated with SARS-CoV-2 (Centers for Disease Control and Prevention 2026a; Koumans et al. 2026). Using CDC burden estimates from the 2023–2024 surveillance year, approximately 33 million symptomatic illnesses were associated with 879,100 hospitalizations, producing an illness-to-hospitalization ratio of about 37.5 infections for every hospitalization.
Applying this ratio to current hospitalization levels produces an estimated 255,000 symptomatic infections per week, or roughly 36,500 symptomatic infections per day. Because not all infections cause symptoms, an additional adjustment is applied. Research suggests that roughly 30–35 percent of SARS-CoV-2 infections may be asymptomatic (Buitrago-Garcia et al. 2020; Sah et al. 2021). Accounting for these infections produces an estimated 54,000 total infections per day in the United States.
Long COVID Estimate Using US-CCUC
The CDC currently reports approximately 17 million adults with Long COVID. However, this estimate relies on strict symptom definitions and passive household surveys. Multiple meta-analyses and cohort studies indicate substantially higher conversion rates, with 10–30% of symptomatic SARS-CoV-2 infections leading to persistent symptoms (Chen et al., 2022; Thaweethai et al., 2023). Earlier CYNAERA public-facing estimates emphasized the conservative correction band. The 2026 revision shifts to the default-high band, reflecting the growing evidence that earlier public estimates understated the true population burden.
Worked Math Box — Long COVID (US-CCUC™ NG) — Updated
Inputs CDC adult baseline: 17M Bias multiplier: 1.9
Math 17M × 1.9 = 32.3M (strict correction)
But Method 4 base range (25.5M–34M) × 1.9 gives:
Low 25.5M × 1.9 = 48.45M
High 34M × 1.9 = 64.6M
Updated adult range 48.5M – 64.6M adults
Default baseline ~65M adults
Long COVID Risk in the Reinfection Era
Research has shown that the risk of Long COVID remains present after reinfection. Early pandemic studies estimated risk levels above ten percent in some populations. More recent research suggests the risk has declined somewhat due to vaccination and prior exposure but remains significant.
Large cohort studies show that individuals remain at risk of post-acute complications even after multiple SARS-CoV-2 infections (Bowe, Xie, and Al-Aly 2022). Population-level studies in both the United Kingdom and the United States also document persistent Long COVID symptoms after reinfection waves (Bosworth et al. 2023). Based on the current research literature, this analysis uses a conservative Long COVID risk range of 2–6 percent per infection.
Estimating New Long COVID Cases
New Long COVID cases are estimated using the following equation:
New cases per day = I × (S/N) × p
Where: I = daily infections S/N = fraction of the population still at risk p = probability of developing Long COVID after infection
Using the parameters described earlier produces the following estimates.
Low estimate
54,000 infections × 0.85 susceptible fraction × 0.02 risk≈ 918 new cases per day
High estimate
54,000 infections × 0.90 susceptible fraction × 0.06 risk≈ 2,916 new cases per day
Using mid-range parameters produces a central estimate of approximately 1,890 new cases per day, which corresponds to roughly 1.3 new Long COVID cases per minute in the United States.
Cases Since the Pandemic Began
Corrected prevalence modeling suggests that approximately 48–65 million Americans may have developed Long COVID since the pandemic began. The largest accumulation occurred during major infection waves in 2021 and 2022, when SARS-CoV-2 transmission was significantly higher than today. During those periods, large numbers of individuals were likely entering the Long COVID disease state each day as infection levels surged across the country. Although transmission levels are lower today than during the peak pandemic years, ongoing infections mean that new cases of Long COVID continue to accumulate over time.
Why the At-Risk Population Grows
The population at risk of Long COVID is not fixed. Several factors continue to expand the group of people who may develop the condition.
These include:
population aging
new birth cohorts entering the population
repeated SARS-CoV-2 infections
underlying health disparities
environmental exposures such as air pollution
Because these factors continue to change over time, the number of people at risk does not remain static. As a result, Long COVID incidence is unlikely to fall to zero without major advances in prevention, treatment, or vaccination strategies.
What These Numbers Mean
Long COVID behaves as a condition that accumulates over time. Even when infection levels fall, continued transmission combined with non-zero risk means new individuals continue to enter the disease state. Based on the estimates presented here, the United States may continue to experience roughly 300,000–600,000 new Long COVID cases each year under current transmission conditions. This continued accumulation has implications for healthcare systems, workforce participation, disability programs, and long-term care needs. Understanding how many new cases are occurring each year is therefore critical for planning research investments, clinical services, and public health responses.
Limitations
This analysis uses hospitalization surveillance as the anchor for estimating infections, which may not capture regional differences in transmission. The illness-to-hospitalization multiplier is based on historical CDC burden estimates and may change over time. Long COVID risk estimates vary across studies depending on case definitions, follow-up periods, and population characteristics. This model also does not account for regional demographic variation. For these reasons, the results are presented as ranges rather than precise counts.
Keeping Estimates Current
The estimates presented in this report depend on several parameters that may change as new surveillance data and research become available. These include the hospitalization-to-infection multiplier used to estimate total infections, the proportion of infections that are asymptomatic, updated estimates of Long COVID risk following infection, and revised prevalence estimates for the number of people already living with the condition. As public health data evolve, these inputs should be periodically reviewed and updated to maintain accurate estimates of ongoing Long COVID incidence. Regular reassessment of these parameters will help ensure that the model continues to reflect current transmission patterns and emerging scientific evidence.
CYNAERA Framework Papers
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library and ME/CFS Library is also a great resource.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and all affiliated CYNAERA frameworks, including CRISPR Remission™, VitalGuard™, CRATE™, SymCas™, and TrialSim™, are protected under U.S. Provisional Patent Application No. 63/909,951.
Licensing and Integration
CYNAERA partners with universities, research teams, federal agencies, health systems, technology companies, and philanthropic organizations. Partners can license individual modules, full suites, or enterprise architecture. Integration pathways include research co-development, diagnostic modernization projects, climate-linked health forecasting, and trial stabilization for complex cohorts. You can get basic licensing here at CYNAERA Market.
Support structures are available for partners who want hands-on implementation, long-term maintenance, or limited-scope pilot programs.
About the Author
Cynthia Adinig is a researcher, health policy advisor, author, and patient advocate. She is the founder of CYNAERA and creator of the patent-pending Bioadaptive Systems Therapeutics (BST)™ platform. She serves as a PCORI Merit Reviewer, and collaborator with Selin Lab for T cell research at the University of Massachusetts.
Cynthia has co-authored research with Harlan Krumholz, MD, Dr. Akiko Iwasaki, and Dr. David Putrino, though Yale’s LISTEN Study, advised Amy Proal, PhD’s research group at Mount Sinai through its patient advisory board, and worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. She has also authored a Milken Institute essay on AI and healthcare, testified before Congress, and worked with congressional offices on multiple legislative initiatives. Cynthia has led national advocacy teams on Capitol Hill and continues to advise on chronic-illness policy and data-modernization efforts.
Through CYNAERA, she develops modular AI platforms, including the CRISPR Remission™, IACC Progression Continuum™, Primary Chronic Trigger (PCT)™, RAVYNS™, and US-CCUC™, that are made to help governments, universities, and clinical teams model infection-associated conditions and improve precision in research and trial design. US-CCUC™ prevalence correction estimates have been used by patient advocates in congressional discussions related to IACC research funding and policy priorities. Cynthia has been featured in TIME, Bloomberg, USA Today, and other major outlets, for community engagement, policy and reflecting her ongoing commitment to advancing innovation and resilience from her home in Northern Virginia.
Cynthia’s work with complex chronic conditions is deeply informed by her lived experience surviving the first wave of the pandemic, which strengthened her dedication to reforming how chronic conditions are understood, studied, and treated. She is also an advocate for domestic-violence prevention and patient safety, bringing a trauma-informed perspective to her research and policy initiatives.
References
Adinig, C. 2026. Transparent Reconstruction of Long COVID Incidence in the United States Using Surveillance Anchors. CYNAERA Institute.
Bowe, B., Y. Xie, and Z. Al-Aly. 2022. Acute and post-acute sequelae associated with SARS-CoV-2 reinfection. Nature Medicine.
Bosworth, M. L., et al. 2023. Risk of Long COVID after reinfection with SARS-CoV-2. Open Forum Infectious Diseases.
Buitrago-Garcia, D., et al. 2020. Occurrence and transmission potential of asymptomatic SARS-CoV-2 infections. PLOS Medicine.
Centers for Disease Control and Prevention. 2026a. COVID-19 Burden Estimates.
Centers for Disease Control and Prevention. 2026b. COVID-19 Hospitalization Surveillance Network (COVID-NET).
Centers for Disease Control and Prevention. 2026c. COVID-19 Surveillance and Modeling Methods.
Koumans, E. H., et al. 2026. Estimated burden of COVID-19 illnesses, medical visits, hospitalizations, and deaths in the United States. JAMA Internal Medicine.
National Academies of Sciences, Engineering, and Medicine. 2024. A Long COVID Definition: A Chronic, Systemic Disease State with Profound Consequences.
Sah, P., et al. 2021. Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis. Proceedings of the National Academy of Sciences.
Comments